Detalhe da pesquisa
1.
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
Nature
; 477(7362): 99-102, 2011 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-21886163
2.
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Mol Ther
; 23(9): 1532-40, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26073886
3.
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.
Mol Ther
; 23(3): 602-8, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25531693
4.
PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Liver Cancer
; 13(3): 248-264, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38756145